HomeLarge Type Edition
HOME ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Download to citation manager
PubMed
Right arrow PubMed Citation
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 62:813-823 (2007)
© 2007 The Gerontological Society of America

Attenuation of Age-Related Muscle Wasting and Weakness in Rats After Formoterol Treatment: Therapeutic Implications for Sarcopenia

James G. Ryall, Jonathan D. Schertzer and Gordon S. Lynch

Basic and Clinical Myology Laboratory, Department of Physiology, The University of Melbourne, Victoria, Australia.

Address correspondence to Gordon S. Lynch, PhD, Department of Physiology, The University of Melbourne, Melbourne, Victoria, 3010 Australia. E-mail: gsl{at}unimelb.edu.au

We investigated the potential of the ß2-adrenoceptor agonist formoterol to increase mass and force-producing capacity of extensor digitorum longus (EDL) and soleus muscles from young, adult, and old rats. In addition, we examined the result of formoterol withdrawal. Young (3 month), adult (16 month), and old (27 month) F344 rats were treated with either formoterol (25 µg/kg/day, i.p.) or saline vehicle for 4 weeks. Another group of rats (for each age) was similarly treated with formoterol, followed by a withdrawal period of 4 weeks. Formoterol treatment increased EDL muscle mass and the force-producing capacity of both EDL and soleus muscles, without a concomitant increase in heart mass in adult and old rats. The hypertrophy and increased force-producing capacity of EDL muscles persisted 4 weeks after withdrawal of treatment. The findings have major implications for potential clinical trials utilizing ß2-agonists for sarcopenia.







HOME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by The Gerontological Society of America.